InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches the new Plugin for Sublime Text editor to highlight Heta language code. Heta project is InSysBio’s initiative for the development of infrastructure for modeling in pharmacology and systems biology. The project also summarizes best practices and InSysBio’s experience in modeling of dynamical systems: systems biology, PK/PD, QSP as well as implementation of software development techniques in modeling routine.
Now Sublime Text supports Heta language due to the new Plugin developed by InSysBio Software Development team. It provides an opportunity for Heta code markup and highlighting in the popular text editor Sublime Text. The Plugin is available in the official repository: https://packagecontrol.io/packages/Heta
Heta infrastructure embraces three components:
Heta language is a domain-specific modeling language (DSL) for dynamic quantitative models used in QSP and systems biology. Heta code and tabular formats can be translated into variety of formats like Simbiology, Matlab, DBSolve and many others. In general, the main purpose of the package is to establish the linkage between emerging QSP frameworks and fast computational methods.
Recently, Heta compiler Online has been presented to simplify user experience. Now it is possible to try Heta compiler without installation or any other additional steps here: https://heta-online.insysbio.com/
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | September 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
1.
09 Sep 2020 14:59
InSysBio to update its Cytocon DB to version 1.2.6.7
InSysBio announces the new version of Cytocon DB 1.2.6.7! Cytocon DB team has reviewed 39 articles to implement the new data. It should be highlighted that the total number of reviewed articles within the Database has already exceeded 515!
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
1.
16 Sep 2020 14:54
InSysBio to take part in ACoP11
InSysBio announces its participation in Eleventh American Conference on Pharmacometrics (ACoP11) which is to be held in virtual format this year due to COVID-19 spread 9-13 November, 2020. The theme of ACoP11 is “Scaling New Heights.” InSysBio team is going to present 9 posters in frames of the Conference
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
1.
23 Sep 2020 10:26
InSysBio announces its collaboration with Genmab
The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB)
[Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
| ||||
Thank you for your message! We will get back to you shortly.
